Literature DB >> 24036811

Comparison studies of different flaps for reconstruction of buccal defects.

Qi-Gen Fang1, Jawad Safdar, Shuang Shi, Xu Zhang, Zhen-Ning Li, Fa-Yu Liu, Chang-Fu Sun.   

Abstract

Our purpose was to evaluate the feasibility of radial forearm free (RFF) flap, platysma myocutaneous (PM) flap, and anterolateral thigh (ALT) flap in buccal reconstruction. This study consisted of 56 patients who were categorized into 3 groups. The Student t test was used to analyze the variables. Patients in group platysma flap were significantly older, the dissection of platysma flap was easier, and the defect was significantly smaller than those in group radial forearm flap and group ALT flap. The reduction in the widths of mouth opening between group PM, group RFF, and group ALT were compared. However, the reduction of mouth-opening widths in group RFF and group ALT was significantly less than that in group PM. Platysma myocutaneous flap may be more suitable in patients with small to middle-size defect and poor status, although the flap cannot achieve a reliable result; anterolateral thigh flap and radial forearm flap can preserve the interincisal distance well even for large buccal defect, but it takes more time and skills in the operation.

Entities:  

Mesh:

Year:  2013        PMID: 24036811     DOI: 10.1097/SCS.0b013e31828b7456

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  2 in total

1.  Pectoralis major myocutaneous flap in salvage reconstruction following free flap failure in head and neck cancer surgery.

Authors:  Wei Wei; Yongsheng Qiu; Qigen Fang; Yingping Jia
Journal:  J Int Med Res       Date:  2018-12-05       Impact factor: 1.671

2.  Platysma myocutaneous flap revised in the free flaps era: clinical experience in 61 patients.

Authors:  Luca Calabrese; Remo Accorona; Luca Gazzini; Giovanni Giorgetti; Marta Tagliabue; Roberto Bruschini; Giacomo Pietrobon; Mohssen Ansarin
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-06       Impact factor: 2.124

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.